Evaluation of insulin use and value for money in type 2 diabetes in the united kingdom

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 51-66

  Gordon, Jason ^a,b   Evans, Marc ^c   McEwan, Phil ^d   Bain, Steve ^e   Vora, Jiten ^f  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HEOR Consulting Pty Ltd   (Australia)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^e SINGLETON HOSPITAL   (United Kingdom)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Costs and cost analysis; Diabetes mellitus; Human insulin; Insulin analog; References; Resource allocation; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; GLYCEMIC CONTROL; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EDUCATION; PRIORITY JOURNAL; SOCIOECONOMICS; UNITED KINGDOM;

EID: 84883173500     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0018-3     Document Type: Article

References (47)

1. World Health Organization 2011. Diabetes fact sheet Number 312. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 5 Oct 2011.
2. Festa A, Williams K, D'Agostino R Jr, et al. The natural course of beta-cell function in nondiabetic and diabetic individuals: the insulin resistance atherosclerosis study. Diabetes. 2006;55:1114-20.
3. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-6.
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
5. Monesi L, Baviera M, Marzona I, et al. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med. 2012;29:385-92.
6. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2: CD005613.
7. QIPP. Cochrane quality and productivity topics. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. http://arms.evidence.nhs.uk/resources/qipp/29481/attachment. Accessed 29 Dec 2012.
8. Holden SE, Poole CD, Morgan CL, et al. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open. 2011;1:1-7.
9. Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12:772-9.
10. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
11. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
12. Gerstein HC, Miller ME, Byington RP, The ADVANCE Collaborative Group, et al. The action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358: 2545-59.
13. Heller SR, Choudhary P, Davies C, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-7.
14. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665-71.
15. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164-70.
16. Alvarez GF, Tofé PS, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10(Suppl. 1): 25-32.
17. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24:87-92.
18. Jönsson B, CODE-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia. 2002;45:S5-12.
19. Exchange rates-X-Rates. http://www.x-rates.com. Accessed 29 Dec 2012.
20. Organization for Economic Co-operation and Development (OECD). "OECD Health Data 2009". http://www.oecd.org/unitedstates/43800977.pdf. Accessed 14 Oct 2011.
21. Rhoads GG, Dain MP, Zhang Q, et al. Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes. Diabetes Obes Metab. 2011;13:711-7.
22. Lee LJ, Yu AP, Johnson SJ, et al. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin Pract. 2010;87:108-16.
23. Schöffski O, Breitscheidel L, Benter U, et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under realworld conditions in Germany: LIVE-SPP study. J Med Econ. 2008;11:695-712.
24. Pscherer S, Dietrich ES, Dippel FW, et al. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. Int J Clin Pharmacol Ther. 2010;48: 129-37.
25. Bretzel RG, Dippel FW, Linn T, et al. Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine. J Med Econ. 2009;12:87-97.
26. Borah BJ, Darkow T, Bouchard J, et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther. 2009;31:623-31.
27. Hammer M, Lammert M, Mejias SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281-90.
28. Lammert M, Hammer M, Frier BM. Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three European countries. J Med Econ. 2009;12:269-80.
29. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
30. Pollock RF, Erny-Albrecht KM, Kalsekar A, et al. Long-acting insulin analogs: a review of "realworld" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev. 2011;7:61-74.
31. NHS Diabetes. Report number 46357 Diabetes in the NHS, 2007. Published by the National Diabetes Support Team on behalf a group of diabetes specialists in England. http://www.diabetes.nhs.uk/document.php?o=318. Accessed 2 Oct 2011.
32. The NHS Information Centre, Prescribing and Primary Care Services. Prescribing for Diabetes in England: 2005/6 to 2010/11. http://www.ic.nhs.uk/webfiles/publications/prescribing%20diabetes%20200506%20to%20201011/Prescribing_for_Diabetes_ in_England_20056_to_201011.pdf. Accessed 4 Oct 2011.
33. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011;13:S53-64.
34. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958-71.
35. Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicarecovered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634-43.
36. Farmer AJ, Brockbank KJ, Keech ML, England EJ, Deakin CD. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med. 2012;29:1447-50.
37. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653-9.
38. The ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-8.
39. HES online: Primary diagnosis-4 character table (2009/10). http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=215. Accessed 9 Oct 2011.
40. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complicat. 2007;21: 220-6.
41. Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29:186-92.
42. Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol. 2005;18:83-91.
43. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9:530-43.
44. Yale JF. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2004;65:S41-6.
45. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16:244-8.
46. Henderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016-21.
47. Merlin T, Lehman S. The benefits and flaws of the Linked Evidence Approach (LEA) to assess diagnostic and screening tests [abstract]. Poster presented at: 7th Annual Meeting, Health Technology Assessment international (HTAi); 6-9 June 2010, Dublin.